oncgnostics at Medica 2022: Cervical cancer screening test conquers China Establishing early detection of head and neck tumours First study results for screening test for vulva and vaginal cancer At […]
The company oncgnostics GmbH, founded in 2012, already launched its first product in 2015: the diagnostic test for cervical cancer “GynTect”. This is now sold in over ten countries in […]
Dr. Carolin Dippmann and Daria Meyer from our research and development team work, among other things, with the “third-generation sequencing” method. With the help of this technology, they are examining […]
We look back on the milestones of 2021 – and forward to upcoming projects. In May, we moved the entire company within Jena, thus gaining space for more office workspace […]
Every year, about 7,300 women in Germany are diagnosed with ovarian cancer (ovarian carcinoma), and more than 5,000 die of the consequences. This means that one in 72 women will […]
As a biotechnology company, we have been researching cancer diagnostics on a molecular basis since 2012. We deal with epigenetic markers, which help us to recognise cancers, such as cervical […]
A large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much […]
What has to be considered if you want to start as a German biotech company on the American market? What are the legal bases and challenges there? We got an […]
Since the beginning of 2020, when early cervical cancer screening in Germany was supplemented by a routine HPV test for women over 35, more people have been confronted with a […]
At the beginning of May, things were turbulent, because we moved into our new offices and laboratories. The new location in a business park in Jena enables us to create […]
